BIOMAT Database Logo BIOMAT Database Logo

Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. 1996

E A Vasiliauskas, and S E Plevy, and C J Landers, and S W Binder, and D M Ferguson, and H Yang, and J I Rotter, and A Vidrich, and S R Targan
Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.

OBJECTIVE Antineutrophil cytoplasmic antibodies (ANCA) have been consistently detected in a subgroup of patients with Crohn's disease (CD). This study was designed to determine whether serum ANCA expression in patients with CD characterizes an identifiable clinical subgroup. METHODS The study population consisted of 69 consecutive patients with an established diagnosis of CD as determined by a combination of characteristic clinical, radiographic, endoscopic, and histopathologic criteria. Sera from the patients were analyzed for the presence of ANCAs using the fixed neutrophil enzyme-linked immunosorbent assay (ELISA) assay. Perinuclear ANCA (pANCA)-positive and cytoplasmic ANCA (cANCA)-positive results by ELISA were confirmed by indirect immunofluorescence staining. Clinical profiles of the ANCA-positive patients with CD were compared with those of patients with CD not expressing ANCA (ANCA-negative). RESULTS pANCA-positive patients with CD have endoscopically and/or histopathologically documented left-sided colitis and symptoms of left-sided colonic inflammation, clinically reflected by rectal bleeding and mucus discharge, urgency, and treatment with topical agents. One hundred percent of patients with CD expressing pANCA had "UC-like" features. CONCLUSIONS In patients with CD, serum pANCA expression characterizes a UC-like clinical phenotype. Stratification of CD by serum pANCA provides evidence of heterogeneity within CD and suggests a common intestinal mucosal inflammatory process among a definable subgroup of patients with CD and UC expressing this marker.

UI MeSH Term Description Entries
D008297 Male Males
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D003093 Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN. Colitis Gravis,Idiopathic Proctocolitis,Inflammatory Bowel Disease, Ulcerative Colitis Type,Ulcerative Colitis
D003424 Crohn Disease A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients. Colitis, Granulomatous,Enteritis, Granulomatous,Enteritis, Regional,Ileitis, Regional,Ileitis, Terminal,Ileocolitis,Crohn's Disease,Crohn's Enteritis,Inflammatory Bowel Disease 1,Regional Enteritis,Crohns Disease,Granulomatous Colitis,Granulomatous Enteritis,Regional Ileitides,Regional Ileitis,Terminal Ileitis
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D019268 Antibodies, Antineutrophil Cytoplasmic Autoantibodies directed against cytoplasmic constituents of POLYMORPHONUCLEAR LEUKOCYTES and/or MONOCYTES. They are used as specific markers for GRANULOMATOSIS WITH POLYANGIITIS and other diseases, though their pathophysiological role is not clear. ANCA are routinely detected by indirect immunofluorescence with three different patterns: c-ANCA (cytoplasmic), p-ANCA (perinuclear), and atypical ANCA. ANCA,Anti-Neutrophil Cytoplasmic Autoantibodies,Anti-Neutrophil Cytoplasmic Autoantibody,Antineutrophil Cytoplasmic Antibodies,Neutrophil Cytoplasmic Autoantibodies,Neutrophil Cytoplasmic Autoantibody,c-ANCA,p-ANCA,Anti-Neutrophil Cytoplasmic Antibodies,Anti-Neutrophil Cytoplasmic Antibody,Antineutrophil Cytoplasmic Antibody,Anti Neutrophil Cytoplasmic Antibodies,Anti Neutrophil Cytoplasmic Antibody,Anti Neutrophil Cytoplasmic Autoantibodies,Anti Neutrophil Cytoplasmic Autoantibody,Antibody, Anti-Neutrophil Cytoplasmic,Antibody, Antineutrophil Cytoplasmic,Autoantibody, Anti-Neutrophil Cytoplasmic,Autoantibody, Neutrophil Cytoplasmic,Cytoplasmic Antibody, Anti-Neutrophil,Cytoplasmic Antibody, Antineutrophil,Cytoplasmic Autoantibody, Anti-Neutrophil,Cytoplasmic Autoantibody, Neutrophil,c ANCA,p ANCA

Related Publications

E A Vasiliauskas, and S E Plevy, and C J Landers, and S W Binder, and D M Ferguson, and H Yang, and J I Rotter, and A Vidrich, and S R Targan
Atypical perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease.
January 1997, Canadian journal of gastroenterology = Journal canadien de gastroenterologie,
E A Vasiliauskas, and S E Plevy, and C J Landers, and S W Binder, and D M Ferguson, and H Yang, and J I Rotter, and A Vidrich, and S R Targan
Perinuclear-antineutrophil cytoplasmic antibodies are associated with vasculitis.
April 2001, International journal of cardiology,
E A Vasiliauskas, and S E Plevy, and C J Landers, and S W Binder, and D M Ferguson, and H Yang, and J I Rotter, and A Vidrich, and S R Targan
Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease.
September 2003, Inflammatory bowel diseases,
E A Vasiliauskas, and S E Plevy, and C J Landers, and S W Binder, and D M Ferguson, and H Yang, and J I Rotter, and A Vidrich, and S R Targan
Ulcerative colitis and perinuclear antineutrophil cytoplasmic antibodies.
April 1998, Journal of clinical pathology,
E A Vasiliauskas, and S E Plevy, and C J Landers, and S W Binder, and D M Ferguson, and H Yang, and J I Rotter, and A Vidrich, and S R Targan
Do pANCA define a clinical subgroup in patients with Crohn's disease?
January 1997, Gastroenterology,
E A Vasiliauskas, and S E Plevy, and C J Landers, and S W Binder, and D M Ferguson, and H Yang, and J I Rotter, and A Vidrich, and S R Targan
Sudden jaundice with isolated atypical perinuclear antineutrophil cytoplasmic antibodies.
November 1999, Annals of internal medicine,
E A Vasiliauskas, and S E Plevy, and C J Landers, and S W Binder, and D M Ferguson, and H Yang, and J I Rotter, and A Vidrich, and S R Targan
[Prevalence of perinuclear antineutrophil cytoplasmic antibodies (pANCA) in inflammatory bowel disease].
June 2004, Medicina clinica,
E A Vasiliauskas, and S E Plevy, and C J Landers, and S W Binder, and D M Ferguson, and H Yang, and J I Rotter, and A Vidrich, and S R Targan
Atypical perinuclear antineutrophil cytoplasmic antibodies after colectomy in inflammatory bowel disease.
January 1997, Canadian journal of gastroenterology = Journal canadien de gastroenterologie,
E A Vasiliauskas, and S E Plevy, and C J Landers, and S W Binder, and D M Ferguson, and H Yang, and J I Rotter, and A Vidrich, and S R Targan
Target antigens for perinuclear antineutrophil cytoplasmic antibodies in Iranian patients with ulcerative colitis.
October 2014, Middle East journal of digestive diseases,
E A Vasiliauskas, and S E Plevy, and C J Landers, and S W Binder, and D M Ferguson, and H Yang, and J I Rotter, and A Vidrich, and S R Targan
Inflammatory Bowel Disease and Its Association With Perinuclear Antineutrophil Cytoplasmic Antibodies: A Systematic Review.
April 2024, Cureus,
Copied contents to your clipboard!